多潘立酮治疗胃轻瘫症状:NIDDK胃轻瘫联盟动态队列研究结果
该研究基于NIDDK胃轻瘫临床研究联盟注册队列,纳入748例胃轻瘫或胃轻瘫样症状患者,其中181例在多潘立酮组、567例未使用多潘立酮。多潘立酮组在胃轻瘫核心症状指数总分、恶心、饱胀、上腹痛、胃食管反流及生活质量评分上均较对照组有中度但显著的改善。
核心结论
- 在大规模GpCRC数据库中使用实效性建模评估长期治疗,多潘立酮治疗使胃轻瘫症状获得中度但显著的改善。
研究设计与样本
- 多中心前瞻性动态队列研究,基于NIDDK胃轻瘫临床研究联盟注册队列(GpR1和GpR2),共纳入748例患者。
- 多潘立酮组为入组96周内开始治疗者(181例,24%),排除入组前已使用或入组时正在使用多潘立酮者;对照组为入组前后均未使用多潘立酮者(567例)。
主要发现
- 基线时多潘立酮组较非多潘立酮组显著更年轻、体重指数更低、非西班牙裔、家庭年收入更高、麻醉药使用更少、补充和替代药物使用更少。
- 基线时多潘立酮组更可能胃排空延迟,且恶心和饱胀评分更差。
临床怎么用
- 对于胃轻瘫患者,多潘立酮治疗可能带来中度但具有统计学意义的症状和生活质量改善。
- 需注意多潘立酮组基线症状更重且胃排空延迟比例更高,临床决策时应结合患者个体特征。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The use of domperidone (DOM) for gastroparesis (GP) remains controversial and limited. We aimed to present outcomes of DOM therapy for treatment of patients participating in the multicenter National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium (GpCRC) Registries (GpR). METHODS: The GpCRC cohort consisted of patients with GP (75%) and with GP-like symptoms but with normal gastric emptying (25%). The DOM group initiated therapy during the 96 weeks of enrollment in GpR1 and GpR2. Patients who had previously taken or who were on DOM therapy at enrollment were excluded from this analysis. The control group did not use domperidone (non-DOM group) before or after enrollment. The following outcome measures were identified: change from baseline in Gastroparesis Cardinal Symptom Index total score, with 3 subscales, plus Gastroesophageal Reflux Disease and Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life scores. RESULTS: Overall, of 748 patients, 181 (24%) were in the DOM group, whereas 567 were in the non-DOM group. Sixty-three percent of participants had idiopathic GP. At baseline, DOM patients compared with non-DOM patients were significantly younger, had lower body mass index, non-Hispanic ethnicity, a higher annual household income, lower narcotic utilization, lower supplemental and complimentary medication use, and were more likely to have delayed gastric emptying time, as well as worse nausea and fullness scores. Compared with non-DOM patients, DOM patients experienced moderate but significantly more improvement in GP outcome measures: Gastroparesis Cardinal Symptom Index total score (P = .003), nausea (P = .003), and fullness subscales (P =.005), upper abdominal pain score (P = .04), Gastroesophageal Reflux Disease score (P = .05), and Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life score (P = .05). CONCLUSIONS: Utilizing the method of pragmatic modeling to evaluate long-term treatment of GP in a large GpCRC database, DOM treatment resulted in moderately but significantly improved GP. NOTE: This project was based on data generated by 2 GpCRC Registry studies recognized under the Clinicaltrial.gov numbers: NCT00398801 and NCT01696747 symptoms compared with a group receiving standard-of-care but not DOM.
引用
- Sarosiek I, Van Natta M, Parkman HP, et al. Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. Clin Gastroenterol Hepatol. 2021. PMID: 34089855. doi:10.1016/j.cgh.2021.05.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。